Osteogenic Differentiation of Human Mesenchymal Stromal Cells is Promoted by a Leukocytes Containing Fibrin Matrix

Overview

Journal Langenbecks Arch Surg

Specialty General Surgery

Date 2010 Jan 21

PMID 20087746

Citations 2

Authors

Dominik Seybold

Thomas A Schildhauer

Jan Gessmann

Gert Muhr

Manfred Koller

Bernd Roetman

Affiliations

Soon will be listed here.

Abstract

Purpose: Mesenchymal stem cells (multipotent human mesenchymal stromal cells, MSC) are currently the most promising cell type for regenerative medicine. For a clinical approach, it is necessary to develop and establish methods for expansion, differentiation, and delivery.

Methods: A completely autologous plasma clot containing peripheral blood mononuclear cells (PBMC) was tested for the osteopromotive activity towards expanded human mesenchymal stem cells in vitro. The plasma clot was prepared from anticoagulated blood plasma after addition of isolated leukocytes and calcium chloride. Plasma clots after the gelation were added to subconfluently growing MSC or used in a transwell system. Cell proliferation, the activity of alkaline phosphatase, the release of osteoprotegerin, C-terminal procollagen peptide, as well as osteocalcin, the analysis of matrix mineralization as well as bone nodule formation were analyzed up to 3 weeks.

Results: In contrast to plasma clots with no exogenously added leukocytes, the presence of PBMC within the plasma clot significantly promoted osteogenic differentiation of MSC correlated to the time period of incubation. Proliferation of MSC was decreased at maximal mineralization time points. In addition, the osteopromotive activity was identified as soluble factor/factors by transwell assay system. There was a decrease in osteoprotegerin when the cells were cultured in the presence of plasma clots compared to control cell cultures without plasma clots. The osteocalcin expression was continuously higher after culture in the presence of plasma clots and significantly higher after 2- and 3-week after culture in the presence of leukocyte-containing plasma clots compared to 1-week cell culture. Differences in the concentration of the C-terminal procollagen peptide were not measured.

Conclusions: The direct inoculation of an autologous mononuclear cell fraction (which contains leukocytes and MSC), e.g., isolated from a bone marrow aspirate or a different source into an autologous plasma gel, may be a further new strategy for bone fracture therapy.

Citing Articles

New Solutions for Old Problems: How Reproductive Tissue Engineering Has Been Revolutionizing Reproductive Medicine.

Leonel E, Dadashzadeh A, Moghassemi S, Vlieghe H, Wyns C, Orellana R Ann Biomed Eng. 2023; 51(10):2143-2171.

PMID: 37468688 DOI: 10.1007/s10439-023-03321-y.

Alignment of the Fibrin Network Within an Autologous Plasma Clot.

Gessmann J, Seybold D, Peter E, Schildhauer T, Koller M Tissue Eng Part C Methods. 2015; 22(1):30-7.

PMID: 26544864 PMC: 4722607. DOI: 10.1089/ten.tec.2015.0207.

References

Schildhauer T, Chapman J, Muhr G, Koller M . Cytokine release of mononuclear leukocytes (PBMC) after contact to a carbonated calcium phosphate bone cement. J Biomed Mater Res A. 2006; 78(1):104-9. DOI: 10.1002/jbm.a.30784. View

Wong C, Inman E, Spaethe R, Helgerson S . Fibrin-based biomaterials to deliver human growth factors. Thromb Haemost. 2003; 89(3):573-82. View

Agis H, Kandler B, Fischer M, Watzek G, Gruber R . Activated platelets increase fibrinolysis of mesenchymal progenitor cells. J Orthop Res. 2008; 27(7):972-80. DOI: 10.1002/jor.20819. View

Shi S, Kirk M, KAHN A . The role of type I collagen in the regulation of the osteoblast phenotype. J Bone Miner Res. 1996; 11(8):1139-45. DOI: 10.1002/jbmr.5650110813. View

Mosesson M . Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005; 3(8):1894-904. DOI: 10.1111/j.1538-7836.2005.01365.x. View

Trombi L, Mattii L, Pacini S, DAlessandro D, Battolla B, Orciuolo E . Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. J Orthop Res. 2007; 26(2):176-83. DOI: 10.1002/jor.20490. View

Flick M, LaJeunesse C, Talmage K, Witte D, Palumbo J, Pinkerton M . Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest. 2007; 117(11):3224-35. PMC: 2000806. DOI: 10.1172/JCI30134. View

Catelas I, Sese N, Wu B, Dunn J, Helgerson S, Tawil B . Human mesenchymal stem cell proliferation and osteogenic differentiation in fibrin gels in vitro. Tissue Eng. 2006; 12(8):2385-96. DOI: 10.1089/ten.2006.12.2385. View

Rifas L, Arackal S, Weitzmann M . Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. J Cell Biochem. 2003; 88(4):650-9. DOI: 10.1002/jcb.10436. View

10.

English D, Andersen B . Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J Immunol Methods. 1974; 5(3):249-52. DOI: 10.1016/0022-1759(74)90109-4. View

11.

Huang N, Lam A, Fang Q, Sievers R, Li S, Lee R . Bone marrow-derived mesenchymal stem cells in fibrin augment angiogenesis in the chronically infarcted myocardium. Regen Med. 2009; 4(4):527-38. PMC: 2778008. DOI: 10.2217/rme.09.32. View

12.

Vanella L, Kim D, Asprinio D, Peterson S, Barbagallo I, Vanella A . HO-1 expression increases mesenchymal stem cell-derived osteoblasts but decreases adipocyte lineage. Bone. 2009; 46(1):236-43. PMC: 2818489. DOI: 10.1016/j.bone.2009.10.012. View

13.

Wolberg A . Thrombin generation and fibrin clot structure. Blood Rev. 2007; 21(3):131-42. DOI: 10.1016/j.blre.2006.11.001. View

14.

Wrotniak M, Bielecki T, Gazdzik T . Current opinion about using the platelet-rich gel in orthopaedics and trauma surgery. Ortop Traumatol Rehabil. 2007; 9(3):227-38. View

15.

Baumgartner L, Arnhold S, Brixius K, Addicks K, Bloch W . Human mesenchymal stem cells: Influence of oxygen pressure on proliferation and chondrogenic differentiation in fibrin glue in vitro. J Biomed Mater Res A. 2009; 93(3):930-40. DOI: 10.1002/jbm.a.32577. View

16.

Catelas I, Dwyer J, Helgerson S . Controlled release of bioactive transforming growth factor beta-1 from fibrin gels in vitro. Tissue Eng Part C Methods. 2008; 14(2):119-28. DOI: 10.1089/ten.tec.2007.0262. View

17.

Wright H, McCarthy H, Middleton J, Marshall M . RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med. 2009; 2(1):56-64. PMC: 2684955. DOI: 10.1007/s12178-009-9046-7. View

18.

Deschaseaux F, Sensebe L, Heymann D . Mechanisms of bone repair and regeneration. Trends Mol Med. 2009; 15(9):417-29. DOI: 10.1016/j.molmed.2009.07.002. View

19.

Rock G, Neurath D, Lu M, Alharbi A, Freedman M . The contribution of platelets in the production of cryoprecipitates for use in a fibrin glue. Vox Sang. 2006; 91(3):252-5. DOI: 10.1111/j.1423-0410.2006.00788.x. View

20.

Kode J, Mukherjee S, Joglekar M, Hardikar A . Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy. 2009; 11(4):377-91. DOI: 10.1080/14653240903080367. View